Weight Loss During Treatment of Hepatitis C in HIV

描述（由申请人提供）：丙型肝炎病毒（HCV）目前是合并感染人类免疫缺陷病毒（HIV）患者的最常见死因。在美国，1/3的HIV感染者同时感染HCV。HIV/HCV合并感染与肝纤维化、肝硬化和肝衰竭的快速进展相关。因此，HCV治疗对于HIV/HCV合并感染患者的长期生存至关重要。然而，据报道，约70%的HIV/HCV患者在HCV治疗期间出现严重的体重减轻，这可能导致过早停止或修改HCV治疗。由于这种不良反应可能会阻止晚期肝病高危患者接受最佳治疗，因此需要确定接受HIV/HCV双重治疗的HIV/HCV患者体重减轻的发生率和程度。这项回顾性队列研究旨在研究双重治疗的HIV/HCV患者与1）接受HCV治疗的HCV单感染患者和2）仅接受HIV治疗的HIV单感染个体相比，体重减轻的发生率。还将检查减肥的风险因素。这项流行病学研究的结果可能最终有助于对HIV/HCV患者的HCV进行最佳治疗，并为评估伴随体重减轻的身体成分和代谢异常变化提供基础。

DESCRIPTION (provided by applicant): Hepatitis C virus (HCV) is now the most common cause of death in patients coinfected with the human immunodeficiency virus (HIV). In the U.S., 1/3 of all HIV-infected patients are coinfected with HCV. HIV/HCV coinfection has been associated with rapid progression of liver fibrosis, cirrhosis, and hepatic failure. Thus, HCV therapy is critical for long-term survival of HIV/HCV-coinfected patients. However, -70% of HIV/HCV patients have been reported to develop severe weight loss during treatment of HCV, and this can result in premature cessation or modification of HCV therapy. Since this adverse effect can prevent patients at high- risk of advanced liver disease from receiving optimal therapy, determination of the incidence and degree of weight loss among HIV/HCV patients receiving dual HIV/HCV therapy is needed. Studies that also elucidate risk factors for weight loss can enhance understanding of biological mechanisms behind it. This retrospective cohort study seeks to examine the incidence of weight loss in dually treated HIV/HCV patients compared to 1) HCV-monoinfected patients who receive HCV therapy and 2) HIV-monoinfected individuals receiving only HIV therapy. Risk factors for weight loss will also be examined. The results of this epidemiological study may ultimately help to allow optimal treatment of HCV in HIV/HCV patients and provide the foundation to evaluate changes in body composition and metabolic abnormalities accompanying weight loss.